Vitamin D3 for Life

Live Enlightened

Article

Renal Vitamin D Activation: Study Summary

Previous related pageRenal Vitamin D Activation: Full Evidence ReviewNext related pageResponsible Interpretation of Vitamin D Science
Study at a glance

Which DNA sections help control vitamin D activation in mouse kidneys?

Researchers used genetically modified mice to study control of vitamin D activation in the kidneys. They removed two different sections of DNA that control Cyp27b1, the gene for an enzyme used in the final activation step. They then tested the effects of parathyroid hormone, another hormone called FGF23, and active vitamin D.

What happened when the first section was removed?

The gene’s usual activity fell by about 95%, and parathyroid hormone could no longer increase it normally. These mice developed low calcium and phosphate, very high parathyroid hormone and extremely low FGF23. The result showed that this DNA region was necessary for the normal response to parathyroid hormone in the tested mice.

How did the second change differ?

Removing the other section reduced usual gene activity by about 75%. parathyroid hormone could still increase activity, but FGF23 and active vitamin D could no longer reduce it normally. These mice maintained calcium and phosphate much more effectively. Other parts of the control system partly made up for the disruption. Relatively normal mineral levels did not mean that the underlying controls were normal.

Can these results from mice guide vitamin D treatment in people?

The study tested large, deliberate DNA changes in mice. It does not establish ordinary human responses, treatment targets or supplement requirements. Calcium and phosphate were mainly measured as parts of the resulting mineral balance. They were not tested as direct controls of the DNA regions in the same way as the hormones. The findings describe how this system can work in mice, not how to set personal treatment.

Read the full article below ↓

This study examined how the kidney regulates the final activation step of vitamin D metabolism. Using genetically modified mice, the researchers investigated control of Cyp27b1, the gene encoding CYP27B1, which converts 25-hydroxyvitamin D3 [25(OH)D3] to the active hormone 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. They identified distinct kidney-specific regulatory regions involved in stimulation by parathyroid hormone (PTH) and suppression by fibroblast growth factor 23 (FGF23) and 1,25(OH)2D3. The study also showed how disruption of this regulatory machinery affected the wider calcium: phosphate and vitamin D homeostatic system.

For the complete methodological analysis and evidence boundaries, see Renal Vitamin D Activation: Full Evidence Review.

What question did this study investigate?

The researchers wanted to understand how endocrine signals regulate renal Cyp27b1 expression and therefore control the final activation step of vitamin D metabolism.

The study focused particularly on PTH, FGF23 and 1,25(OH)2D3. PTH stimulates renal Cyp27b1 expression, whereas FGF23 and 1,25(OH)2D3 suppress it. The researchers investigated whether these different hormonal effects depend on distinct regulatory regions associated with the Cyp27b1 gene.

The wider physiological question was how disruption of this regulatory system would affect vitamin D metabolism and calcium: phosphate homeostasis in living animals.

What was studied?

Study design: Primary in-vivo and molecular experimental study using genetically modified mouse models.

Experimental system: Wild-type mice and genetically modified mice carrying targeted deletions of kidney-specific regulatory regions associated with Cyp27b1.

Interventions: Treatment with PTH, FGF23 or 1,25(OH)2D3, together with targeted deletion of genomic regulatory regions involved in renal Cyp27b1 expression.

Primary relevant outcome: Regulation of renal Cyp27b1 expression and the physiological consequences of disrupting that regulation.

How was the study carried out?

The researchers first examined the genomic region surrounding Cyp27b1 to identify kidney-specific regulatory elements. They then deleted selected regulatory regions in mice so that their functions could be tested experimentally.

Two genetically modified models were particularly informative. M1-IKO mice lacked a regulatory region within Mettl1, while M21-IKO mice lacked a different regulatory region within Mettl21b.

The researchers then tested how renal Cyp27b1 responded to PTH, FGF23 and 1,25(OH)2D3. They also measured vitamin D metabolites, calcium, phosphate, PTH, FGF23 and other components of vitamin D metabolism, allowing molecular regulation to be examined alongside its wider physiological consequences.

What did the researchers find?

The study showed that different parts of the kidney-specific regulatory system controlled different hormonal responses.

In M1-IKO mice, basal renal Cyp27b1 expression was reduced by approximately 95%, and the normal stimulatory response to PTH was lost. These animals developed major disturbances in vitamin D and mineral homeostasis, including hypocalcaemia, hypophosphataemia, markedly elevated PTH and extremely low FGF23.

In M21-IKO mice, basal Cyp27b1 expression was reduced by approximately 75%. However, these animals retained responsiveness to PTH while losing normal suppression of Cyp27b1 by FGF23 and 1,25(OH)2D3.

Despite this substantial molecular disruption, M21-IKO mice maintained calcium and phosphate concentrations much more effectively than M1-IKO mice. This demonstrated the capacity of the wider endocrine system to compensate for some disturbances in vitamin D activation.

What does this study support?

The study provides strong mechanistic evidence that renal vitamin D activation is actively regulated rather than functioning as an uncontrolled conversion step. PTH stimulation and FGF23/1,25(OH)2D3 suppression of Cyp27b1 depended on different components of a kidney-specific genomic regulatory system.

The resulting physiological changes also show that regulation of vitamin D activation is integrated with calcium and phosphate homeostasis. Changes in renal Cyp27b1 regulation affected PTH, FGF23, vitamin D metabolism and mineral balance as parts of an interconnected system.

What does this study not establish?

The study does not establish that calcium, phosphate, PTH and FGF23 all act directly and equivalently on Cyp27b1. PTH, FGF23 and 1,25(OH)2D3 were experimentally tested as direct endocrine regulators of renal Cyp27b1 expression. Calcium and phosphate were principally measured as components of the wider homeostatic system.

The findings therefore support an integrated calcium: phosphate: PTH: FGF23 framework surrounding renal vitamin D activation without demonstrating the same molecular mechanism for every component.

The study also does not establish human regulatory thresholds, clinical target concentrations or vitamin D supplementation requirements. It was a mechanistic mouse experiment rather than a human clinical study.

What are the main limitations?

The principal limitation is that the experiments were conducted in genetically modified mice. The findings provide powerful in-vivo mechanistic evidence, but the exact genomic architecture and magnitude of endocrine responses cannot automatically be assumed to be identical in humans.

The targeted genomic deletions were also deliberately substantial experimental disruptions. They are useful for identifying which regulatory regions are necessary for particular hormonal responses, but the resulting phenotypes should not be interpreted as ordinary physiological variation.

Finally, apparently normal mineral concentrations do not necessarily indicate normal underlying regulation. The M21-IKO animals retained relatively normal calcium and phosphate despite major alterations in Cyp27b1 regulation, illustrating the importance of compensatory endocrine mechanisms.

Why this matters within vitamin D physiology

The final activation of vitamin D is not simply a chemical conversion that proceeds at a fixed rate. Renal CYP27B1 sits within a regulated endocrine network that responds to signals reflecting the body’s mineral and vitamin D physiology.

This study demonstrates that PTH-driven stimulation and FGF23/1,25(OH)2D3-driven suppression can be separated at the level of the genomic machinery controlling renal Cyp27b1. Disrupting those controls can then propagate through vitamin D metabolism and calcium: phosphate homeostasis.

The study therefore helps explain how the kidney functions as a regulated site of vitamin D activation rather than merely as a passive location for the final hydroxylation reaction.

For the broader physiology, see Vitamin D Activation.

For the enzyme pathways involved in vitamin D activation and degradation, see Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1).

For the complete analysis of this study, see Renal Vitamin D Activation: Full Evidence Review.

Primary source and publication details

Meyer MB, Benkusky NA, Kaufmann M, Lee SM, Onal M, et al.

A kidney-specific genetic control module in mice governs endocrine regulation of the cytochrome P450 gene Cyp27b1 essential for vitamin D3 activation.

Journal of Biological Chemistry. 2017;292(42):17541 to 17558.

PMID: 28808057

PMCID: PMC5655528

DOI: 10.1074/jbc.M117.806901

View the verified primary source

Related reading

Original sources